Teach experimental design: randomization, blinding, blocking, factorials, power/sample…
- User
Teach experimental design: randomization, blinding, blocking, factorials, power/sample size, confounding, analysis plans, and preregistration; include examples.
- Assistant
Experimental Design: Key Principles and Best Practices
Experimental design is the blueprint for conducting rigorous, reproducible research. It minimizes bias, controls variability, and ensures valid conclusions. Below, I'll cover the requested topics step-by-step, with clear explanations and real-world examples. We'll use a running example: a clinical trial testing two drugs (A and B) vs. placebo for reducing blood pressure to illustrate concepts.
1. Randomization
What it is: Randomly assigning participants to treatment groups (e.g., via coin flips, random number generators) to ensure groups are comparable and eliminate selection bias. It balances known and unknown confounders across groups.
Why it matters: Prevents systematic differences between groups that could skew results.
Example:
- In our blood pressure trial with 300 patients: Use software to randomly assign 100 to Drug A, 100 to Drug B, and 100 to placebo.
- Without randomization: If sicker patients get Drug A, it might appear less effective.
- Result: Groups have similar age, baseline BP, etc., by chance.
Tip: Simple randomization works for large samples; stratified randomization (see blocking) for small ones.
2. Blinding (Masking)
What it is: Concealing treatment allocation from participants (single-blind), researchers (double-blind), or analysts (triple-blind) to prevent expectation biases.
Why it matters: People behave differently if they know the treatment (e.g., placebo effect).
Example:
- Single-blind: Patients don't know if they're on Drug A or placebo (pills look identical).
- Double-blind: Neither patients nor doctors know (independent pharmacist codes assignments).
- Triple-blind: Data analysts also blinded until analysis.
- In our trial: Blinded patients report symptoms honestly; blinded doctors measure BP objectively. Unblinded? Doctors might subconsciously favor Drug A.
Tip: Breaking the blind (e.g., side effects) requires pre-planned handling.
3. Blocking
What it is: Dividing participants into homogeneous blocks (based on key variables like age or site) before randomizing within blocks. Reduces variability and increases precision.
Why it matters: Controls for known confounders, making treatment effects clearer.
Example:
- In our trial, block by age: Block 1 (under 50), Block 2 (50+). Randomize 33/33/34 per group within each block.
- Agricultural example: Test fertilizers on corn. Block by soil type (sandy/clay) to account for soil affecting yield, not just fertilizer.
- Result: Treatment effect estimated with less noise; power increases.
Tip: Choose blocks based on prior knowledge (e.g., 2-5 per factor).
4. Factorial Designs
What it is: Testing multiple factors simultaneously in a crossed design (e.g., 2x2=4 groups). Efficiently estimates main effects (each factor alone) and interactions (combined effects).
Why it matters: Reveals synergies/antagonisms; saves time/money vs. separate experiments.
Example (2x2 factorial):
- Factors: Drug (A vs. Placebo) x Diet (Low-salt vs. Normal-salt).
- Groups: (1) A + Low-salt, (2) A + Normal, (3) Placebo + Low-salt, (4) Placebo + Normal.
- Main effect: Does Drug A lower BP overall?
- Interaction: Does low-salt amplify Drug A?
- Result: One trial answers multiple questions. If interaction, low-salt + A drops BP by 20mmHg vs. 5mmHg alone.
Tip: Higher-order (e.g., 2x2x2) for 3+ factors, but watch sample size explosion.
Group Drug A Placebo Low-salt Group 1 Group 3 Normal-salt Group 2 Group 4 5. Power and Sample Size
What it is: Statistical power = probability (usually 80-90%) of detecting a true effect (if it exists). Sample size calculation ensures this, based on effect size, alpha (0.05), power, and variability.
Why it matters: Underpowered studies miss real effects (Type II error); overpowered waste resources.
Example:
- Assume: Detect 10mmHg BP drop (effect size), SD=15mmHg, alpha=0.05, power=80%.
- Formula/software (e.g., G*Power): Need ~64 per group (t-test).
- For factorial: Adjust for multiple comparisons.
- Result: With n=100/group, power=90% → reliable results.
Tip: Pre-calculate: Power = 1 - β. Use simulations for complex designs.
6. Confounding
What it is: A third variable (confounder) associated with both treatment and outcome, creating spurious links. Design (randomization/blocking) or stats (regression) control it.
Why it matters: Leads to wrong conclusions (e.g., "ice cream causes drowning" – confounder: summer heat).
Example:
- In our trial: Smoking confounds if smokers (higher baseline BP) preferentially get Drug B.
- Solution: Randomization balances it; or block by smoking status; or adjust in analysis (ANCOVA).
- Observational pitfall: Coffee drinkers seem smarter – confounder: education.
Tip: Identify via DAGs (Directed Acyclic Graphs); never ignore.
7. Analysis Plans
What it is: Detailed, pre-written protocol specifying hypotheses, tests, covariates, multiplicity corrections (e.g., Bonferroni), and handling missing data.
Why it matters: Prevents data dredging (p-hacking) and flexible analyses.
Example:
- Plan: "Primary: t-test BP change (Drug A vs. Placebo). Secondary: ANOVA for factorial. Covary baseline BP/age. ITT analysis. Alpha=0.05."
- In trial: No post-hoc subgroups unless planned.
Tip: Include decision trees for interim looks.
8. Preregistration
What it is: Publicly registering study design, hypotheses, and analysis plan (e.g., on OSF.io, ClinicalTrials.gov) before data collection.
Why it matters: Commits to plan, reduces questionable research practices (QRPs), builds trust.
Example:
- Preregister: "RCT, n=300, primary outcome=BP at 12 weeks, power calc provided. Analysis: Intention-to-treat linear mixed model."
- Post-data: Can't add "surrogate marker" outcome.
- Famous case: Many psych studies failed replication due to undisclosed flexibility.
Tip: Timestamped, uneditable (but amendable with justification).
Putting It All Together: A Gold-Standard Design
- Design: 2x2 factorial RCT, preregistered, blocked by age/site, randomized, double-blind.
- Sample: Power calc → n=400.
- Analysis plan: Pre-specified GLM with confounders.
- Outcome: Valid, reproducible BP drug insights.
Final Tips
- Trade-offs: Balance power, cost, ethics.
- Software: R (experimentr), JASP for design; G*Power for power.
- Checklist: CONSORT for trials; follow it!
- Practice: Design a fertilizer trial on wheat yield.
Questions? Let's refine an example for your field! 🕵️♂️
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.